Lexicon Pharmaceuticals closed a $94.6 million public offering of 32 million common shares at $1.30 per share and a concurrent private placement of 22.4 million common shares and 367,145 Series B convertible preferred shares at $65 per share on February 2, 2026. The company plans to use net proceeds for research and development of drug candidates and general corporate purposes.

Lexicon Pharmaceuticals closed a $94.6 million public offering of 32 million common shares at $1.30 per share and a concurrent private placement of 22.4 million common shares and 367,145 Series B convertible preferred shares at $65 per share on February 2, 2026. The company intends to use the net proceeds to fund research and development of drug candidates and for general corporate purposes. Underwriters were granted a 30-day option to purchase up to 4.8 million additional shares.

Lexicon Pharmaceuticals announced the pricing of a $94.6 million capital raise consisting of a $41.6 million public offering of 32 million common shares at $1.30 per share and a $52.9 million concurrent private placement to Invus affiliate. The offering is expected to close February 2, 2026, with proceeds designated for R&D of drug candidates and general corporate purposes.

A clinical study demonstrated sotagliflozin's potential benefits for heart failure patients with preserved ejection fraction (HFpEF) without diabetes, showing significant improvements in cardiac structure, function, and quality of life.

Lexicon Pharmaceuticals submitted additional clinical data to the FDA for Zynquista®, an oral SGLT1/SGLT2 inhibitor for type 1 diabetes, following a complete response letter in December 2024. The FDA requires more time to review the data and will provide feedback in Q4 2025.

Lexicon Pharmaceuticals will present patient survey data on diabetic peripheral neuropathic pain (DPNP) at the American Society of Pain and Neuroscience meeting, highlighting their investigational non-opioid treatment pilavapadin.

U.S. stock futures fell on Monday after three consecutive days of decline. Goldman Sachs has increased its U.S. recession probability from 20% to 35% and warned that the risk of further market correction is still looming.

Three small-cap stocks, Argan, Lightwave Logic, and Lexicon Pharmaceuticals, posted significant gains last week despite broader market uncertainty, with Lexicon surging 58% on a licensing deal with Novo Nordisk.

Lexicon Pharmaceuticals reported progress on its pipeline, including positive topline results for its DPNP drug candidate pilavapadin and continued enrollment in a Phase 3 trial for its SGLT1/2 inhibitor sotagliflozin in hypertrophic cardiomyopathy. The company also provided financial results for Q4 2024 and full-year 2024.

Lexicon Pharmaceuticals will announce topline results from a Phase 2b study evaluating pilavapadin, an investigational drug for diabetic peripheral neuropathic pain. The study enrolled 496 adult patients with moderate to severe diabetic peripheral neuropathic pain.

George Medicines, a late-stage biopharmaceutical company, has appointed Amy Carroll, Ph.D., as Senior Vice President of Medical Affairs. Carroll brings over 20 years of experience in medical affairs from leading global pharmaceutical companies.

The type 1 diabetes (T1D) market is expected to grow at a strong CAGR of 13.3% from 2023 to 2033, reaching $9.91 billion. Key drivers include the increased use of rapid-acting insulins, insulin pumps, and immunomodulatory therapies, as well as the rising global prevalence of T1D. However, high prices, patent expiries, and the failure of disease-modifying therapies in clinical trials pose challenges to market growth.